OTC Link · Healthcare · Drug Manufacturers - Specialty & Generic
PROPHASE LABS INC
ProPhase’s only real catalyst is the Crown Medical Collections update on legacy COVID receivables, but the core business is still deteriorating badly. Q1 revenue was just **$478k** and an **$4M** operating loss underscores a weak, cash-consuming turnaround rather than a recoverable specialty healthcare platform.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Q1 2026 | — | -0.43 | — | $478,000 | — | +0.00% | -2.39% | — |
| 2026-06-01 | Q4 2025 | — | -2.34 | — | $784,000 | — | +0.00% | -13.42% | -30.74% |
| 2025-11-19 |
| Q3 2025 |
| -0.11 |
| -0.16 |
| -45.45% |
| $883,000 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -0.15 | -0.11 | +26.67% | $1.2M | mixed | -1.13% | +0.73% | +32.41% |
| 2025-03-31 | Q4 2024 | -1.27 | -1.59 | -25.20% | $-2.5M | ❌ Miss | -0.07% | -32.95% | -13.93% |
| 2024-11-13 | Q3 2024 | 0.04 | -0.35 | -975.00% | $3.1M | ❌ Miss | -2.42% | -0.65% | -15.45% |
| 2024-08-14 | Q2 2024 | -0.24 | -0.33 | -37.50% | $2.5M | ❌ Miss | -9.60% | +13.20% | -2.00% |
| 2023-08-10 | Q2 2023 | -0.14 | -0.20 | -42.86% | $13.2M | ❌ Miss | -2.23% | -14.15% | -30.21% |
Showing last 8 quarters.